These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 33946843)

  • 21. Role and effective therapeutic target of gut microbiota in NAFLD/NASH.
    Liu Q; Liu S; Chen L; Zhao Z; Du S; Dong Q; Xin Y; Xuan S
    Exp Ther Med; 2019 Sep; 18(3):1935-1944. PubMed ID: 31410156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease, diet and gut microbiota.
    Finelli C; Tarantino G
    EXCLI J; 2014; 13():461-90. PubMed ID: 26417275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis.
    Plaza-Díaz J; Solis-Urra P; Aragón-Vela J; Rodríguez-Rodríguez F; Olivares-Arancibia J; Álvarez-Mercado AI
    Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33546191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver and the gut microbiota.
    Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
    Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal Microbiota Transplantation in NAFLD Treatment.
    Abenavoli L; Maurizi V; Rinninella E; Tack J; Di Berardino A; Santori P; Rasetti C; Procopio AC; Boccuto L; Scarpellini E
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363516
    [No Abstract]   [Full Text] [Related]  

  • 28. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
    Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microbial Metabolites: Critical Regulators in NAFLD.
    Dai X; Hou H; Zhang W; Liu T; Li Y; Wang S; Wang B; Cao H
    Front Microbiol; 2020; 11():567654. PubMed ID: 33117316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut Dysfunction and Non-alcoholic Fatty Liver Disease.
    Grabherr F; Grander C; Effenberger M; Adolph TE; Tilg H
    Front Endocrinol (Lausanne); 2019; 10():611. PubMed ID: 31555219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
    Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms.
    Jasirwan COM; Lesmana CRA; Hasan I; Sulaiman AS; Gani RA
    Biosci Microbiota Food Health; 2019; 38(3):81-88. PubMed ID: 31384519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Not Available].
    Buffet C
    Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
    Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
    Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
    Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
    Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review.
    Castillo V; Figueroa F; González-Pizarro K; Jopia P; Ibacache-Quiroga C
    Foods; 2021 Jul; 10(8):. PubMed ID: 34441497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.